





### Medical Device Regulations: impact and implications Dr. Gurge Phull

### Agenda






### Story



### Regulations development





### The path





### Where to find the MDR





### Directive vs. Regulation

#### **EU DIRECTIVES**


Lay down certain end results that must be achieved in each member state however the countries are free to decide how to implement these. VS. a

### **EU REGULATIONS**

Are direct EU law(s), applicable as soon as they are passed and are legally binding in all member states as part of their national law.




### MDD vs. MDR







The documents are large and very complex





### What's similar?

**Essential requirements** 

**Risk Based Classification** 

Use of standards

Third party review



### What's changed?

Safety & performance requirements

Additional classification rules

Clinical evaluation strengthened

Post market surveillance increased

Scrutiny

Transparency



### What does this mean?





### Annex 1: General Safety & Performance Requirements

Software (inc. standalone), privacy and security (cyber)

Devices with a medicine or biological function

Biological safety / specified chemical carcinogens / hormones etc.

Label & Information


Standards / other sources like European pharmacopeia

Lay people risks

Cleaning, sterilisation & disinfection (contamination or microbial state)




### **Device - Classes**






### Annex VIII - Classification





### **Details - Classes**





### Clinical evidence



### Evaluation

### Data



### **Clinical evaluations**

Clinical Evaluation Report (MEDDEV 2.7/1 Rev 4)

Benefit/Risk evaluation

Will be scrutinised (data & methodology) by NB & CA

Increased data requirements


Data will only be accepted from equivalent device (biology/technical/ clinical)

Equivalent device(s) need full access to Technical Files and Data

Many current "equivalent devices" will no longer be accepted




### Clinical investigations






### Post-market





### Key Players





### Traceability requirements

### Manufacturers information

### UDI for each device

Devices, information, clinical investigations, incidents etc.

Update reports

### Using EUDAMED



### Obligations of the manufacturer (EUAR / EO)

Ensure devices are designed and manufactured in accordance with the regulation (MDR/QMS)

Establish, execute, maintain and document a system for risk management (MDR/QMS/14971)

Gather clinical evidence, including post-market clinical follow-up (ISO14155 & MEDDEV 2.7/1 Rev 4 & MDR Annexes)

Prepare and update the technical documentation

Qualified personnel RA/QA



### Steps to Compliance





### Impact on existing devices





### Impact on existing devices

No Grandfathering

Must be State of the Art

Must have Clinical evidence

**Quality Management System** 

**Correct Labelling** 

**RoHS/WEEE/REACH** considerations



### Grandfathering?

"A grandfather clause is a provision in which an old rule continues to apply to some existing situations while a new rule will apply to all future cases.

Those exempt from the new rule are said to have grandfather rights or acquired rights, or to have been grandfathered in." - Wikipedia



State of the Art?

"State of the art means what is currently and generally accepted as good practice" – ISO14971 Annex D.4

Some examples on how to ensure your device is state of the art:
use of current standards for the same or similar devices
best practices as used in other devices of the same or similar type
Results from accepted scientific literature



### **Clinical Evidence?**

Clinical justifications based on device equivalence to be less accepted Expected to show: - Technical - Biological - Clinical



### QMS

### QMS necessary to achieve compliance

MDR article 10, clause 9 QMS to address at least:

- Risk Management
- Clinical Evaluation
- Product Realisation especially design controls
- Verification of UDI
- Plan, Implementation and maintenance of PMS system
- Communication with stakeholders
- Process of reporting
- Process of monitoring and product improvement



Refer to TR17223:2018 for Mapping 13485 to MDR article 10

### **Business Risk & implications**

Risk of having non compliant product

Compliance planning / timelines

Reclassification / up-classification of products

**Technical File revisions** 

Reduced Notified Body capacity

Vigilance and Post Market Surveillance

UDI and registration of products

Increase resources (budget, training, outsourcing, testing etc.)



### Other considerations

### EUDAMED


### Common Specifications

### BREXIT

#### Resources



### Transition timeline



### Timelines

26 May 2017	MDR 2017/745
26 November 2017	Notified Bodies designation
26 March 2020	EUDAMED go live date
26 May 2020	MDR date of application
26 May 2022	IVDR date of application
26 May 2024	AIMD, MDD and IVDD certificates become void
26 May 2025	no devices may be put into service in Europe using MDD, AIMD or IVDD certificates



## So ... are you ready?



# Questions

